A competitive ligand-binding assay for the detection of neutralizing antibodies against dostarlimab (TSR-042)

A competitive ligand-binding assay for the detection of neutralizing antibodies against dostarlimab (TSR-042)

Abstract Dostarlimab is a humanized anti–PD-1 monoclonal antibody. Dostarlimab (JEMPERLI; TSR-042) was recently approved in the USA and in the EU. The presence of neutralizing antibodies (NAbs) is a cause for concern because they block the therapeutic function of the antibody and reduce drug efficac...

Full description

Bibliographic Details
Main Authors: Xiaolong Tom Zhang, Hong Chen, Weiping Shao, Zhongping John Lin, Murad Melhem, Sharon Lu
Format: Article
Language:English
Published: SpringerOpen 2021-11-01
Series:AAPS Open
Subjects:
Dostarlimab
Endometrial cancer
Neutralizing antibodies
Immunotherapy
Competitive ligand-binding assay
Online Access:https://doi.org/10.1186/s41120-021-00039-w

Internet

https://doi.org/10.1186/s41120-021-00039-w

Similar Items